GLP-1, an incretin hormone, exerts anorexigenic effects by enhancing satiety and reducing gastric emptying, and has become a central focus in obesity treatment through GLP-1 receptor agonists [185,186]. This evidence concerns the gene GLP1R and obesity disorder.